SLC3A1 Mitigates Ferroptosis and Promotes Enzalutamide Resistance in Prostate Cancer
Results reveal SLC3A1 is a promising therapeutic target for advanced prostate cancer and its association with adverse prognosis and activation of key survival pathways is confirmed.